Specialities

Diabetology

Hypertension and nephrology

FEBRUARY 26, 2022

[Telmisartan plus amlodipine single-pill combination therapy to achieve blood pressure goal values in hypertensive patients treated by general practitioners – an observational study]

ÁMON Tamás, BARACSI-BOTOS Viktória, MÉSZÁROS Ágota, JÁRAI Zoltán

[Background: Current European guidelines on the management of hypertension suggests a simple and easily applicable therapeutic strategy to increase effectiveness. Important component of this strategy is the application of single-pill combination (SPC) of RAS inhibitor in combination with calcium antagonists or diuretics as a first step. Primary objective: To assess the percentage of patients reached goal blood pressure ranges after 12 weeks of fix dose combination therapy with telmisartan plus... tovább »

Hypertension and nephrology

FEBRUARY 26, 2022

[Beyond the blood sugar reduction. SGLT-2 inhibitors in kidney protection]

SIMONYI Gábor

[Results of cardiovascular safety studies with SGLT-2 inhibitors have shown that in addition to their hypoglycaemic and beneficial cardiovascular effects, they are renoprotective. A number of mechanisms underlying the renoprotective effects of SGLT-2 inhibitors have been shown to reduce albuminuria and deterioration of renal function. Their nephroprotective effects extend over a very wide range of eGFR and albuminuria categories. In the DAPA-CKD study, dapagliflozin was shown to exert its... tovább »

Hypertension and nephrology

FEBRUARY 26, 2022

[Lupus nephritis, 2022]

CZIROK Szabina, DOLGOS Szilveszter

[The lupus nephritis (LN) is one of the most frequent manifestation of SLE which causes higher morbiditiy and mortalitiy of the patients if it appears. Although the use of glucocorticoides, cyclophosphamide and mycofenolat mofetil and the protection of the kidney with conservative therapy has significantly improved the outcome of the disease, but the long-term renal outcome and risk of death from LN have not changes over the last 20 years. Furthermore, the side effect of our medications used as... tovább »

Lege Artis Medicinae

FEBRUARY 24, 2022

[Cardiovascular prevention 2021 – Guidelines of European Society of Cardiology 2021. Prevention at the population level And Disease specific cardiovascular prevention]

VÁLYI Péter, KÉKES Ede

[In our four-part publication we review the current state of cardiovascular prevention based on the European Society of Car­dio­logy Guidelines 2021. In part 1 we reviewed the risk factors, risk assessment, age-specificities, the influencing factors, including diabetes mellitus and chronic kidney disease. In part 2 we concerned comorbidities affecting the cardiovascular risk. In part 3 we reviewed the personalised cardiovascular prevention and the management of specific risk factors, including... tovább »

Lege Artis Medicinae

FEBRUARY 24, 2022

[Main features of cardiovascular rehabilitation in post-acute Covid-19]

JENEI Zoltán, HORVÁTH Judit

[The COVID-19 pandemic caused by SARS-CoV-2 is a significant challenge worldwide. Cornerstones of in-patient management of this pandemic which harms predominantly the respiratory system are the acute and intensive care. However, the rehabilitation plays a key role in improving the functional status and quality of life of survivors and reducing the impact of complications. As estimated, 40-50% of discharged patients require some form of medical support and 4-5% of them require inpatient... tovább »

Lege Artis Medicinae

FEBRUARY 24, 2022

[Non-alcoholic fatty liver disease]

BAFFY György

[Non-alcoholic fatty liver disease is estimated to affect 25% of the global population. It is often joining other metabolic disorders and features a heterogeneous natural history. Significant liver injury is unlikely to develop from steatosis, while a third of steatohepatitis cases will progress into cirrhosis and as a severe complication may lead to primary liver cancer. The probability of these severe outcome increases with the degree of liver fibrosis and with the prevalent type 2 diabetes... tovább »